1Y Close · As of Aug 26, 2026
EyeGene operates in the Professional Services sector.
Legal name: EyeGene,Inc
In fiscal year 2025, EyeGene (185490) reported revenue of 3.6 billion KRW, up 6.3% from 3.4 billion KRW a year earlier.
Operating profit was -9.9 billion KRW and net income was -19.1 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 80.8 billion KRW, with a P/B of 1.49.
These figures can be verified in the DART filing (receipt no. 20260319000655).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 3.6B | -9.9B | -19.1B |
| 2024 | 3.4B | -13.3B | -12.9B |
| 2023 | 3.1B | -27.1B | -22.4B |
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-03 | Officer/Major Shareholder Ownership Report |